Three weeks into taking on the role of Lexicon Pharmaceuticals CEO back in 2024, Michael Exton told Fierce the company close its commercial operations.
- Home |
- With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’
With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’
- May 13, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
